论文部分内容阅读
表皮生长因子受体 (epidermalgrowthfactorreceptor,EGFR)信号传递系统可调控细胞周期 ,调节细胞生长与分化 ,促进损伤修复。EGFR在包括非小细胞肺癌 (non small celllungcancer,NSCLC)在内的多种上皮源性肿瘤中过表达预示存活率低、预后差、转移可能性大 ,可作为肿瘤基因治疗的靶位。酪氨酸激酶抑制剂 (tyrosinekinaseinhibitors,TKIs)可选择性抑制EGFR酪氨酸激酶活性 ,抑制肿瘤生长 ,增加放化疗敏感性
Epidermal growth factor receptor (EGFR) signal transduction system can regulate the cell cycle, regulate cell growth and differentiation, and promote injury repair. Overexpression of EGFR in many epithelial-derived tumors, including non-small cell lung cancer (NSCLC), predicts a low survival rate, poor prognosis, and a high probability of metastasis. EGFR can serve as a target for gene therapy of tumors. Tyrosine kinase inhibitors (tyrosinekinase inhibitors, TKIs) can selectively inhibit EGFR tyrosine kinase activity, inhibit tumor growth, increase chemoradiation sensitivity